Trial Profile
Phase Ib Study of Ficlatuzumab With High Dose Cytarabine (HiDAC) in Relapsed and Refractory AML
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ficlatuzumab (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 08 Dec 2020 Results of sub-analysis assessing the mechanisms of drug resistance in specific subsets of heterogeneous cell population through Single cell RNA sequencing presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 22 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 18 Aug 2019 Status changed from recruiting to active, no longer recruiting.